GlassScriptPhysician profile
Ahmed Masood
NPI 1528047305
$4,044.08
in general payments reported to CMS, 2019-2025
33 companies · $699 in 2025
The $699 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,037 · 2020: $480 · 2021: $157 · 2022: $499 · 2023: $627 · 2024: $545 · 2025: $699.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,448 · Education: $423.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,447.70 |
| Education | $422.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $687.07 | 2019-2025 | Ofev |
| Astrazeneca Pharmaceuticals LP | $610.27 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Actelion Pharmaceuticals US, INC. | $480.20 | 2019-2024 | Uptravi, Opsumit |
| Insmed, INC. | $382.91 | 2019-2025 | Arikayce, Brinsupri |
| Genentech USA, INC. | $309.57 | 2019-2025 | Xolair |
| Glaxosmithkline, LLC. | $308.93 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Medtronic Vascular, INC. | $169.91 | 2020 | |
| Electromed, INC. | $166.75 | 2024-2025 | Smartvest |
| Harmony Biosciences LLC | $126.64 | 2020-2023 | Wakix |
| Genzyme Corporation | $113.89 | 2019-2023 | |
| Inari Medical, INC. | $68.81 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Philips North America LLC | $63.59 | 2021-2023 | |
| Amgen INC. | $52.14 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $49.07 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $44.60 | 2019-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $42.57 | 2019 | |
| Grifols USA, LLC | $41.42 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $40.86 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.72 | 2022 | |
| United Therapeutics Corporation | $35.11 | 2019 | |
| Fisher & Paykel Healthcare INC | $34.25 | 2021-2025 | Fisher & Paykel Healthcare |
| Jazz Pharmaceuticals INC. | $30.74 | 2019-2020 | |
| Advanced Respiratory, INC | $27.78 | 2020 | |
| Vapotherm INC | $23.50 | 2023 | Vapotherm |
| Boston Scientific Corporation | $21.58 | 2023 | Exalt Model D |
| E.R. Squibb & Sons, L.L.C. | $17.47 | 2024 | Eliquis |
| Merck Sharp & Dohme LLC | $15.55 | 2023 | |
| Abbvie INC. | $13.52 | 2022 | |
| Sunovion Pharmaceuticals INC. | $12.93 | 2019 | |
| Portola Pharmaceuticals, LLC | $11.73 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmed Masood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.